BioBridgeX
Log inCompare quotes
Modality

Gene Editing (CRISPR-based) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a CRISPR gene-editing program means handing specialist CROs and CDMOs the editor design and screening, off-target and on-target characterization, GLP safety work, and GMP manufacture of the editing components, whether that is mRNA plus guide RNA in lipid nanoparticles, AAV-delivered editors, or ex vivo edited cells. On BioBridgeX, buyers source and compare qualified suppliers, then contract directly with their chosen supplier, free for buyers.

Gene Editing (CRISPR-based) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Gene Editing (CRISPR-based) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Gene Editing (CRISPR-based) drug?

A CRISPR program is really several programs stacked together, and the outsourcing map depends on which delivery route you picked. The biology splits into the editor itself (Cas9, Cas12a, a base editor, or a prime editor), the guide RNA that aims it, and the delivery vehicle that gets both into the right cells. Each of those is a separate body of work with its own suppliers, and a generalist CRO that is strong on small-molecule tox will not have the assays or the regulatory scar tissue for any of it.

Discovery and lead optimization for an editor is mostly guide design and screening: nominating guides against the target locus, measuring editing efficiency, and then doing the work that actually defines a CRISPR program, which is characterizing where else the editor cuts. Off-target analysis is the technical heart of the modality. You are buying GUIDE-seq, CIRCLE-seq or SITE-seq, amplicon deep sequencing of nominated sites, and increasingly an honest look at on-target consequences too: large deletions, chromosomal rearrangements, and translocations that simple indel counting misses. For base and prime editors you add bystander editing and, for base editors specifically, RNA off-target and guide-independent DNA editing. A supplier that only quotes you in-silico off-target prediction is not equipped for this.

Then the work bifurcates by delivery, and this is where CDMO selection gets specific. For in vivo programs the dominant route is now mRNA encoding the editor plus a synthetic or chemically modified guide RNA, co-formulated in a lipid nanoparticle, so you need a CDMO with IVT mRNA capability, capped and modified-nucleotide chemistry, large-scale solid-phase guide RNA synthesis, and LNP formulation and encapsulation. An AAV-delivered editor pulls you into viral-vector manufacturing instead, with all the capsid, full-empty ratio, and titer questions that come with it. Ex vivo programs (the edited cell therapies, including CAR-T made with a knockout) need a cell-therapy CDMO that can run electroporation or LNP delivery into the patient or donor cells under GMP, plus the apheresis-to-product chain. Sitting under all of it is analytical method development for a modality regulators are still writing the rulebook on: editing-efficiency assays, off-target panels qualified to GMP, residual Cas protein and residual nuclease testing, and identity and potency assays that an inspector will accept. Specialist gene-editing CDMOs differ from generalists mainly here, in having built and defended these methods before, and in knowing what the FDA's human gene therapy and genome editing guidances actually expect in a filing.

How do you choose a CRO or CDMO for Gene Editing (CRISPR-based)?

Match the supplier to your delivery route and your edit type first, because the wrong-shaped partner is the most expensive mistake here. An LNP-mRNA in vivo program, an AAV-delivered editor, and an ex vivo edited cell product are three different supply chains with three different supplier shortlists, and a base or prime editor needs characterization assays a plain nuclease shop may not run. Get two or three suppliers quoting against the same written scope, and weigh them on the points below.

Two quieter questions decide more than the headline capabilities. Ask how a supplier handles on-target structural consequences, not just off-target cutting, because large deletions and translocations are where this field has been burned and a thorough partner will raise it before you do. And ask, plainly, how many gene-editing programs they have actually taken to the stage you need, since this modality has far more suppliers claiming capability than suppliers with a real track record.

  • Relevant platform and track record: confirm hands-on experience with your specific editor class (nuclease, base editor, prime editor) and delivery route (LNP-mRNA, AAV, ex vivo), and ask for redacted examples of programs they have run to your stage, not just a capability slide.
  • Off-target and on-target characterization depth: look for empirical methods (GUIDE-seq, CIRCLE-seq, SITE-seq, deep amplicon sequencing) plus assessment of large deletions, rearrangements, and translocations, and for base editors, bystander and RNA off-target work, never in-silico prediction alone.
  • GxP and analytical capability for this modality: GLP for the IND-enabling safety package and GMP for clinical supply, with editing-efficiency, residual nuclease, residual Cas, identity, and potency assays already developed and qualified rather than promised.
  • Capacity and scale: realistic queue and lead time, and the right manufacturing fit, IVT mRNA and guide RNA synthesis plus LNP formulation for in vivo, viral-vector suites for AAV, or GMP cell-processing for ex vivo, at the scale your phase needs.
  • Regulatory experience: a record of supporting IND or CTA filings for genome-editing products, familiarity with FDA human gene therapy and genome editing guidance and long-term follow-up expectations, and EMA or other regional experience if you are filing there.
  • IP and confidentiality: a CDA before you name the target or share guide sequences, clear ownership of program data and any edits made, and a sober read on CRISPR licensing exposure, since the underlying patent landscape can affect freedom to operate for your editor and delivery system.

Frequently asked questions

What is the difference between a CRO and a CDMO for a CRISPR program?
A CRO runs the research and development services: guide design and screening, editing-efficiency and off-target characterization, GLP toxicology, and the IND-enabling safety package. A CDMO manufactures the actual drug substance and product under GMP, which for gene editing means IVT mRNA and guide RNA synthesis with LNP formulation for in vivo programs, viral-vector production for AAV-delivered editors, or GMP cell processing for ex vivo edited cells. Many programs use several specialist suppliers across both, which is the whole reason comparing quotes and contracting directly with each in one place is useful.
Why does off-target analysis matter so much when choosing a gene-editing supplier?
Off-target editing is the safety question that defines this modality, and it is the area where supplier quality varies most. A weak partner quotes you in-silico off-target prediction, which only narrows where to look. A strong one runs empirical, genome-wide methods (GUIDE-seq, CIRCLE-seq, SITE-seq) plus deep amplicon sequencing of nominated sites, and increasingly characterizes on-target consequences too: large deletions, chromosomal rearrangements, and translocations that simple indel counting misses. For base and prime editors you also need bystander editing and, for base editors, RNA off-target assessment. Whether a supplier raises the on-target structural questions before you do is one of the clearest signals of how experienced they actually are.
Which delivery method should I plan my CRISPR manufacturing around?
It depends on whether you are editing cells inside the body or outside it. Most in vivo programs now use mRNA encoding the editor plus a synthetic guide RNA, co-formulated in a lipid nanoparticle, so you need a CDMO with IVT mRNA, guide RNA synthesis, and LNP formulation capability. AAV-delivered editors route you into viral-vector manufacturing, with capsid, titer, and full-empty ratio considerations. Ex vivo programs, including edited cell therapies, need a cell-therapy CDMO that can deliver the editor into cells under GMP and run the apheresis-to-product chain. Each route has a different supplier shortlist, so the delivery decision largely sets your manufacturing partner.
Do I need GLP and GMP for an early CRISPR program?
Yes, at the right points. Early discovery (guide screening, editing optimization, exploratory off-target work) is research-grade and does not need GLP. The definitive safety studies that support your IND or CTA do need GLP, and any material dosed into humans must be made under GMP. For gene editing the harder part is analytical: editing-efficiency assays, off-target panels, residual nuclease and residual Cas testing, and identity and potency assays should be developed and qualified to a standard a regulator will accept. A supplier that has already built and defended these methods saves you significant time over one developing them on your program.
What regulatory experience should a gene-editing CRO or CDMO have?
Look for a record of actually supporting genome-editing IND or CTA filings, not just gene-therapy filings in general, since editing carries specific expectations. The supplier should be fluent in the FDA's human gene therapy and genome editing guidance, including the heightened attention to off-target and on-target genomic integrity and the long-term follow-up requirements that come with permanent edits. If you plan to file with the EMA or another regional authority, confirm experience there too. Regulatory expectations for this modality are still maturing, so a partner who has been through a recent filing is worth a premium over one working from theory.
How does BioBridgeX handle a CRISPR program that needs several different suppliers?
That is the situation BioBridgeX is built for. A single gene-editing program can need a discovery CRO, a GLP toxicology lab, an mRNA or guide RNA manufacturer, an LNP formulation house, and an analytical group, each a separate specialist. BioBridgeX acts as the neutral marketplace, so you compare quotes and contract directly with each chosen supplier in one place. It is free for buyers, with a flat 2% fee paid by suppliers, and covers all indications and modalities, so you can compare qualified suppliers and route the whole program through one relationship.

Source Gene Editing (CRISPR-based) work with one contract

Compare transparent quotes from qualified Gene Editing (CRISPR-based) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes